Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):39–44. doi: 10.1097/QAI.0b013e31829ed7a4

Table 1. Pharmacokinetics of DTG in BP, SF, RF, and RT following single and multiple doses.

Matrix t1/2 (h) Tmax (h) Cmax (ng/mL, swab or g) C24h (ng/mL, swab or g) AUC0-24h (ng*h/mL, swab or g) AUC0-inf (ng*h/mL, swab or g) Matrix:BP AUC0-24h ratio
BP Single Dose 12.2 (11.2-14.2) 4 (2-5) 2285 (1790-2743) 704 (580-874) 31335 (24948-39970) 44902 (37253-58911) -
Multiple Doses 14.1 (12.0-16.1) 2.5 (1-3) 2945 (2120-3400) 954 (554-1093) 41320 (28092-47219) 60553 (37785-70036) -
SF Single Dose 7.7 12 140 46.6 2018 2445 0.07
Multiple Doses 11.5 (8.5-14.8) 3.5 (3-6) 244 (190-323) 57.9 (47.6-94.0) 3229 (2439-4376) 4210 (3567-6377) 0.07 (33)
RF Single Dose - 24 17.0 17.0 91.9 - -
Multiple Doses - 12 (6-12) 26.5 (8.0-289) 8.6 (0.9-88.9) 300 (73.6-3160) - -
RT Single Dose 4.1 6 373 114 5281 5890 0.17
Multiple Doses 8.4 4 418 139 7596 9617 0.17

Parameter estimates are presented as median (IQR) or point estimates for parameters generated from composite profiles. BP multiple dose estimates were calculated from concentrations following the last dose. Matrix:BP ratios are presented as the geometric mean AUC0-24h ratio (%CV) for SF after a single dose or geometric mean AUC0-24h ratio for RT and SF after multiple doses.